FDA approves diabetes drug that also helps with weight loss

TRENTON, N.J. — U.S. regulators on Tuesday authorized a new diabetes drug that reduces blood sugarine levels and also helps people remove poignant weight. Danish drugmaker Novo Nordisk pronounced a Food and Drug Administration authorized a once-a-week shot for people with Type 2 diabetes. The drug, Ozempic, also famous as semaglutide, works by sensitive a body’s possess insulin prolongation and shortening appetite.

In one large company-funded study, Ozempic, on average, reduced long-term blood sugarine levels during slightest 2 ½ times as most as a renouned daily diabetes pill, Merck Co.’s Januvia. It also helped investigate participants remove dual to 3 times as most weight as those in a comparison group.

Over 56 weeks, patients who got a revoke sip of Ozempic mislaid an normal of 9.5 pounds (4.3 kilograms) while those who got a aloft sip mislaid 13.5 pounds (6.1 kilograms). The patients who took Januvia mislaid an normal of 4 pounds (1.9 kilograms).

The 1,200 investigate participants were also holding one or dual customary diabetes medicines.

Novo Nordisk, a personality in diabetes care, has also been contrast a drug alone for weight loss alone.

Many Type 2 diabetes patients are overweight or obese, and losing poignant weight customarily helps them revoke their blood sugarine and improved control their diabetes. Over time, too high sugarine in a blood can repairs mixed viscera and break circulation.

The new drug comes in injector pens and costs about a same as identical weekly drugs: $676 for a four- to six-week supply but insurance. Novo Nordisk already sells a identical once-a-day shot, Victoza.

Ozempic will contest with other renouned once-a-week drugs in a same class, including Eli Lilly and Co.’s Trulicity and AstraZeneca PLC’s Bydureon, that don’t furnish as most weight loss. However, they all lift warnings about probable critical side effects, including kidney repairs and inflammation of a pancreas. They also might be related to thyroid cancer, so people holding all drugs in a category are being followed around a studious registry.

Januvia is in a opposite drug class.

Short URL: http://hitechnews.org/?p=48801

Posted by on Dec 7 2017. Filed under Health & Medicine. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

Leave a Reply

Photo Gallery

Log in | Designed by hitechnews